Nrf2-related gene expression is impaired during a glucose challenge in type II diabetic rat hearts

Free Radic Biol Med. 2019 Jan:130:306-317. doi: 10.1016/j.freeradbiomed.2018.10.405. Epub 2018 Oct 11.

Abstract

Diabetic hearts are susceptible to damage from inappropriate activation of the renin angiotensin system (RAS) and hyperglycemic events both of which contribute to increased oxidant production. Prolonged elevation of oxidants impairs mitochondrial enzyme function, further contributing to metabolic derangement. Nuclear factor erythriod-2-related factor 2 (Nrf2) induces antioxidant genes including those for glutathione (GSH) synthesis following translocation to the nucleus. We hypothesized that an acute elevation in glucose impairs Nrf2-related gene expression in diabetic hearts, while AT1 antagonism would aid in Nrf2-mediated antioxidant production and energy replenishment. We used four groups (n = 6-8/group) of 25-week-old rats: 1) LETO (lean strain-control), 2) type II diabetic OLETF, 3) OLETF + angiotensin receptor blocker (ARB; 10 mg olmesartan/kg/d × 8 wks), and 4) ARBM (4 weeks on ARB, 4 weeks off) to study the effects of acutely elevated glucose on cardiac mitochondrial function and Nrf2 signaling in the diabetic heart. Animals were gavaged with a glucose bolus (2 g/kg) and groups were dissected at T0, T180, and T360 minutes. Nrf2 mRNA was 32% lower in OLETF rats compared to LETO and remained suppressed in response to glucose. LETO Nrf2 mRNA increased 25% at T360 in response to glucose while no changes were observed in diabetic hearts. GCLC and GCLM mRNA decreased in diabetic hearts 33% and 44% respectively and remained suppressed in response to glucose while ARB treatment increased GCLM transcripts 90% at T180. These data illustrate that during T2DM and in response to glucose, cardiac Nrf2's adaptive response to environmental stressors such as glucose is impaired in diabetic hearts and that ARB treatment may aid Nrf2's impaired dynamic response.

Keywords: AT1; GSH; Hyperglycemia; Mitochondrial dysfunction; Nrf2.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Antioxidants / pharmacology*
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Gene Expression Regulation / drug effects
  • Glucose / metabolism
  • Glutathione / biosynthesis
  • Heart / drug effects
  • Humans
  • Insulin Resistance / genetics
  • NF-E2-Related Factor 2 / genetics*
  • Oxidants / pharmacology
  • Oxidative Stress / genetics
  • Rats
  • Receptor, Angiotensin, Type 1 / genetics*
  • Renin-Angiotensin System / drug effects
  • Signal Transduction / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Antioxidants
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat
  • Oxidants
  • Receptor, Angiotensin, Type 1
  • Glutathione
  • Glucose